Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacogenomics of Paclitaxel in Ovarian Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by University of Southern Denmark.
Recruitment status was  Active, not recruiting
Danish Clinical Intervention Research Academy
Ministry of the Interior and Health, Denmark
Information provided by:
University of Southern Denmark Identifier:
First received: December 21, 2006
Last updated: June 22, 2012
Last verified: December 2006

This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this in patients with ovarian cancer who receive paclitaxel/carboplatin chemotherapy after primary surgery.

Ovarian Neoplasms
Fallopian Tube Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Pharmacogenomics of Paclitaxel in Patients With Ovarian Cancer: Predictors of Toxicity and Response

Resource links provided by NLM:

Further study details as provided by University of Southern Denmark:

Biospecimen Retention:   Samples With DNA


Estimated Enrollment: 100
Study Start Date: September 2006
Estimated Study Completion Date: March 2013
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Paclitaxel is an antineoplastic drug used in the treatment of ovarian cancer. The effect and toxicity is unpredictable in the individual patient. Paclitaxel is removed (eliminated) from the organism by oxidation. CYP2C8 is the enzyme mainly responsible. P-glycoprotein (Pgp) is an efflux transport protein natural to the human organism. Pgp is responsible for excretion of drugs via the bile and the kidneys and is thought to play a role in chemotherapy resistance. Paclitaxel is substrate for Pgp. Single nucleotide polymorphisms are possible causes for variation in both CYP2C8 and Pgp expression/function. We will study a possible role of these genetic variations as predictors of paclitaxel toxicity and effect and the possible implications for individual dosing in the future.

We want to determine the metabolic capacity of approximately 100 ovarian cancer patients and comparing this with genotypes, acute toxicity(eg. bone marrow suppression and neuropathy) and response to treatment(ie. CA125 response, progression free survival and overall survival). The metabolic capacity is estimated using a "sparse sampling" approach applying advanced computerized pharmacokinetic/dynamic modelling as opposed to traditional "frequent sampling" pharmacokinetic studies which burden the individual patient more.

Patients are recruited in collaboration with Oncological departments throughout Scandinavia.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients diagnosed with ovarian cancer


Inclusion Criteria:

  • Clinical diagnose and histology of invasive epithelial ovarian/tuba or peritoneal cancer
  • FIGO stage IIb-IV any grade or FIGO Ia-IIa only grade 3 or clear cell carcinoma (any stage and grade)
  • Natural candidate for paclitaxel 175mg/m2 + Carboplatin (AUC=5-6)
  • Baseline CA125≥70 AND/OR evaluable disease after RECIST (incl ultrasound)
  • 18 years or older
  • Caucasian (ie.parents and grandparents are Caucasian)
  • Performance status 2 or lower (after WHO/ECOG)

Exclusion Criteria:

  • Prior malignant disease apart from cervical carcinoma in situ and basal cell carcinoma of the skin
  • Prior chemo / radiotherapy
  • Ongoing or imminent other chemotherapies
  • Pregnant or lactating
  • Fertile woman of childbearing potential not willing to use adequate contraception
  • Neurological symptoms (any kind) worse than CTCAE grade 1
  • Active infection or other serious disease that could impair on treatment and/or follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415181

Department of oncology, Herlev Hospital
Herlev, Denmark
Department of Oncology, Odense University Hospital
Odense, Denmark
Department of Oncology, Vejle Hospital
Vejle, Denmark
Department of Oncology, University Hospital of Lund
Lund, Sweden
Sponsors and Collaborators
University of Southern Denmark
Danish Clinical Intervention Research Academy
Ministry of the Interior and Health, Denmark
Study Director: Kim Brøsen, phd University of Southern Denmark
  More Information

Responsible Party: Troels K Bergmann, University of Southern Denmark Identifier: NCT00415181     History of Changes
Other Study ID Numbers: AKF-319pro
Study First Received: December 21, 2006
Last Updated: June 22, 2012
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by University of Southern Denmark:

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on November 20, 2014